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Baljean Dhillon2,4 and Peter Cackett2,4
Abstract
Background: To assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to
aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD).
Methods: A retrospective case series was conducted on patients who had persistent or recurrent intra- and/or sub-retinal
fluid treated initially with RBZ and subsequently switched to AFL. The main outcome measures were best corrected visual
acuity (BCVA) and central retinal thickness (CRT) measured at different stages of the study. Friedman analysis of variance
and Wilcoxon test were used to examine differences in BCVA and CRT.
Results: Two hundred and seven eyes from 182 patients were included. BCVA and CRT improved significantly initially
following 3 RBZ injections with a mean gain of 3.7 letters (p< 0.001) and a mean loss of 69 μm (p < 0.001) respectively.
Following PRN RBZ therapy and immediately prior to switching to AFL (mean 129 weeks), there was a mean
loss of 6.7 letters (p < 0.001) BCVA and a mean gain of 24 μm (p < 0.001) CRT.
AFL loading resulted in a mean improvement of 0.7 letters (p = 0.28) BCVA and 55 μm (p < 0.001) CRT. At final
follow-up following AFL PRN therapy (mean 85 weeks), there was a mean loss of 8.9 letters (p< 0.001) BCVA and a mean
gain of 12 μm (p < 0.05) CRT.
Conclusion: AFL loading resulted in a significant anatomical improvement but no significant change in visual acuity.
However, the benefits of switching were gradually lost over time with AFL PRN dosing despite an increased
injection rate when compared with RBZ PRN treatment.
Trial registration: Not applicable
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Background
Neovascular age-related macular degeneration (nvAMD)
is one of the leading causes of visual impairment in the
population aged over 50 years of age [1]. The prevalence
of sight threatening nvAMD is predicted to increase
with time [2].
The mainstay of treatment for nvAMD is with intravit-
real administration of drugs targeting vascular endothe-
lial growth factor (VEGF). Ranibizumab (RBZ) [Lucentis,
Genentech, San Francisco, California, USA] was first
licensed by the Federal Drug Administration (FDA) for
the treatment of nvAMD in 2006 and became the most
widely used anti-VEGF agent. RBZ is a monoclonal anti-
body fragment that specifically targets VEGF-A [3].
Large multicentre clinical trials have demonstrated that
RBZ intravitreal therapy (IVT) stabilises long-term best-
corrected visual acuity (BCVA) in the majority of pa-
tients with nvAMD and improves BCVA in a minority
of patients [4, 5]. However, maintaining a frequent treat-
ment schedule for patients with nvAMD is difficult for
patients and places a heavy burden on health services
[6]. As a result a number of variable treatment, follow-
up and dosing schedules have been developed including
pro re nata (PRN) strategies [7–9]. Despite RBZ treat-
ment some patients with nvAMD continue to demon-
strate persistent macular fluid [10]. Taken together this
points to the need to test alternative treatments for
nvAMD in patients who are incompletely treated with
RBZ IVT.
Aflibercept (AFL) [Eylea, Regeneron, Tarrytown, New
Jersey] was FDA-approved as an alternative anti-VEGF
treatment for nvAMD in late 2011. AFL is a recombin-
ant fusion protein consisting of VEGF-binding portions
from the extracellular domains of human VEGF recep-
tors. These protein domains are fused to the Fc portion
of a human immunoglobulin to improve their half-life
[11]. AFL mimics VEGF target receptors and acts to trap
both VEGF-A, VEGF-B and placental growth factor re-
ducing downstream effects of these chemokines. Multi-
centre clinical trials have also confirmed the clinical
efficacy of AFL in the treatment of nvAMD [12]. Add-
itionally, AFL has also been shown to reduce persistent
macular fluid in cases of nvAMD which appear refrac-
tory to treatment with RBZ [13, 14]. AFL has been found
to have a higher binding affinity for VEGF than RBZ
which predicts a lower required concentration and po-
tentially longer clinical effect [15]. AFL administered at
an interval of two months after 3 initial monthly loading
doses, was found to be non-inferior to RBZ in
treatment-naive eyes [12]. The less frequent treatment
regime with AFL and reduced cost of AFL compared
with RBZ treatment for nvAMD also has potential impli-
cations for improved cost-utility when compared with
RBZ in a PRN dosing schedule [16].
Increasingly patients who have initially been treated
with RBZ are being switched to AFL. However, there is a
relative dearth of real world clinical data on the effect of
switching patients using a PRN treatment strategy. In
this study we describe the effects of switching to AFL
PRN therapy in AMD patients who had recurrent
nvAMD despite a RBZ PRN schedule at a regional AMD
treatment centre in the United Kingdom.
Methods
Design & Patients
A retrospective case series was conducted on patients at-
tending the Princess Alexandra Eye Pavilion, Edinburgh,
a tertiary referral centre for nvAMD. A treatment regis-
ter was maintained of all patients who attended the
centre between September 2013 and May 2014 and re-
quired ongoing anti-VEGF treatment. From this register
we identified consecutive patients who were switched
from RBZ to AFL. This therapeutic switch was based on
a change in protocol for treatment instituted by the
department. Switch patients were followed up pro-
spectively for a minimum of 12 months after switch.
Paper-based health records for these patients were
retrospectively reviewed between 1 April 2016 and 26
June 2016.
Verbal informed consent for prospective data collec-
tion was obtained from all participants at the first injec-
tion visit by the treating clinician. The study was given
ethical approval, granted a waiver of documentation of
informed consent for retrospective analysis and ap-
proved for verbal consent with regard to prospective
follow-up by the NHS Lothian research ethics commit-
tee with approval number 09/S1101/05. All procedures
adhered to the tenets of the Declaration of Helsinki.
All inclusion criteria refer to the study eye only. In
order to be included in the study, patients had to have a
diagnosis of nvAMD as demonstrated by changes on ret-
inal examination, optical coherence tomography (OCT)
or fundus fluorescein angiography initially. In addition,
to be switched they had to have persistent or recurrent
intra- and/or sub-retinal fluid on OCT consistent with
active disease at least 6 months after RBZ loading.
Patients must also have had a minimum of 4 RBZ in-
jections which comprised the loading phase (3 con-
secutive monthly injections) followed by at least 1
further injection.
Exclusion criteria for the study eye included best-
corrected visual acuity ≥1.3 logMAR as this exceeded
local guidelines for treatment with anti-VEGF.
Study protocol
For all patients, data was collected at 5 intervals repre-
senting 4 stages of the study (Fig. 1). In stage 1, patients
were reviewed prior to initiating RBZ treatment and
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4 weeks after the third loading dose of RBZ. In stage 2,
patients were then treated with RBZ following a PRN
protocol.
At switch, 3 loading doses of intravitreal AFL (2 mg)
were administered at approximately 4-week intervals.
Stage 3 was from immediately prior to anti-VEGF switch
and 4 weeks after the third loading dose of AFL. In stage
4 patient were treated with AFL again on a PRN sched-
ule and followed up after a minimum of 12 months fol-
lowing AFL switch. For both PRN phases, a decision to
retreat was made if there was evidence of intra- and/or
sub-retinal fluid on SD-OCT.
At all visits, patients underwent a full ophthalmic
examination of both eyes, which included best corrected
visual acuity (BCVA) measured using Early Treatment
Diabetic Retinopathy Study (ETDRS) letters (recorded at
4 m) whilst central retinal thickness (CRT) measured
using OCT. The same Zeiss Cirrus SD-OCT machine
(Carl Zeiss Meditec Inc., Dublin, CA) was used for all
CRT measurements. Additionally, intraocular pressures
and adverse event monitoring was performed at each
visit. Data was also collected on the duration of disease,
the number of injections performed and phakic status. If
follow-up was deemed appropriate, the schedules were
decided by the ophthalmologist depending on activity
and varied between 1 and 4 months.
Injection procedure
All RBZ and AFL injections were performed according
to a standardised protocol in a treatment room setting
by the same healthcare team. Patients were prepared by
administration of topical anaesthesia (Minims tetracaine
hydrochloride 0.5%), followed by application of a topical
antiseptic (povidine iodine 5% or chlorhexidine 0.1% in
the case of documented prior iodine allergy). The injec-
tion was performed using a 30-gauge needle through the
pars plana. All patients were given a one-off dose of
chloramphenicol ointment following injection.
Statistical analysis
The analysis was performed in three parts. Firstly, differ-
ences in BCVA and CRT were examined using a
Friedman analysis of variance followed by Wilcoxon
tests for paired comparisons. Secondly, correlations be-
tween change in BCVA and CRT were analysed by
principle component analysis with varimax rotation.
Finally, a correlated component regression analysis
examining the predictors of change in visual outcome
was carried out at each of the 4 stages of the study [see
Additional file 1 for further details of statistical analyses].
All statistical analyses were carried out using SPSS stat-
istic version 17.0 (IBM Corp., Armonk, N.Y., USA).
Results
Patient characteristics
A total of 213 eyes from 188 patients were identified
from the treatment register; 6 of the 188 patients were
excluded due to missing case notes, leaving 207 eyes
from 182 patients for analysis. A summary of the base-
line details of the participants at switch and duration of
Fig. 1 Diagram summarising the timeline of data collection in this study. All patients had an initial loading phase of 3 monthly injections of RBZ
(stage 1) followed by a PRN treatment schedule with RBZ (stage 2) which was on average 129 (±86) weeks. After switch, patients had 3 loading
monthly injections of AFL (stage 3) followed by PRN AFL (stage 4). The mean time for AFL PRN treatment was 85 (±18) weeks. Data was collected
at baseline (1) and 4-week review post RBZ loading (2). Further data was collected at switch to AFL (3), 4-week review post AFL loading (4) and >
12 months after switch (5)
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AMD by switch and number of RBZ injections is shown
in Table 1. The mean age at switch was 80 years (±7.7)
and 71% of patients were female. The mean duration of
nvAMD in patients was 129 (±86) weeks at switch. Base-
line mean BCVA (±SD) was 29 (±13.2) ETDRS letters
whilst the baseline mean CRT (±SD) was 342 μm (±100).
Patients received monthly RBZ injections for RBZ
loading in stage 1. The mean treatment period during
stage 2 (RBZ PRN) was 129 (±86) weeks with patients
receiving an average of 12 (±7) RBZ injections over
this time.
At switch patients received 3 loading doses of AFL
with a month interval. In stage 4, patients received AFL
PRN therapy. 9 patients were lost to follow-up, 7 pa-
tients were swapped back to RBZ due to poor response
to AFL, and a further 7 patients did not require further
anti-VEGF treatment after AFL loading but continued
under regular follow-up. These latter two groups of pa-
tients are included in the overall analysis as well as a
separate analysis within this paper. The average follow-
up for stage 4 of the study was 85 (±18) weeks with pa-
tients receiving an average of 10 (±3) AFL injections
over this time, achieving an average injection frequency
of 8.6 weeks.
Visual acuity changes
BCVA improved significantly following 3 RBZ loading
injections, with a mean gain of 3.7 ETDRS letters (p <
0.001) when compared to baseline. At switch, BCVA had
deteriorated with a mean loss of 6.7 letters (p < 0.001).
This was a net loss of 3 ETDRS letters from baseline
after a mean treatment period of 129 weeks with a mean
of 12 injections resulting in a mean injection frequency
of an injection every 10.75 weeks.
After AFL loading, the BCVA had increased by a mean
of 0.7 EDTRS letters from switch, although this change
(p = 0.28) was not statistically significant from BCVA at
switch. After the AFL PRN treatment phase mean BCVA
had declined with a mean loss of 8.9 letters (p < 0.001)
over a mean treatment phase of 85 (±18) weeks (Fig. 2).
This resulted in an overall mean loss of 11.2 letters from
baseline with a total mean treatment time of 229 weeks.
The rate of decline of BCVA during RBZ PRN treatment
saw an average loss of 3.2 letters per eye per year. In the
AFL PRN treatment phase BCVA was reduced on aver-
age by 5.5 letters per eye per year. Letters per eye per
year was defined as the total sum of letters gained or lost
divided by the total number of eyes and the total mean
treatment time of the stage examined.
Anatomic changes
Changes in CRT followed a similar trend to BCVA. CRT
decreased by an average of 69 μm (p < 0.001) following
the 3 RBZ loading injections. At switch CRT had in-
creased by a mean of 24 μm (p < 0.001). Following AFL
loading, the CRT showed a significant mean reduction of
55 μm (p < 0.001). After AFL PRN treatment, the CRT
had increased by an average of 12 μm (p < 0.05) (Fig. 3).
Looking at average changes over time per eye per year
for each stage, with RBZ PRN therapy there was an in-
crease in mean CRT of 12 μm per eye per year, which
was reduced to 7 μm per eye per year on AFL PRN.
After AFL loading, 173 eyes (83.6%) showed static or
reduced CRT. However, after a minimum of 12 months
follow-up of patients on AFL PRN treatment only 80
eyes had static or reduced CRT (43%) (Table 2).
A principal component analysis with varimax rotation
was carried out to examine the relationship between
BCVA and CRT during the study. The results showed
that there was a positive correlation between BCVA and
CRT change in stage 1, meaning that better BCVA
was associated with reduced CRT during RBZ loading.
However, this relationship was not maintained in
stages 2, 3 or 4.
To identify predictors of final visual outcome a regres-
sion analysis was used to examine the predictors of
change in BCVA and CRT at each stage of the study.
Better BCVA at the start of stages 1, 2 and 3 was the
only consistent predictor of better BCVA at the end of
each of these stages. In stage 4, higher CRT at switch
and higher CRT post AFL loading predicted better
BCVA. A longer time from first presentation to switch
predicted better BCVA after AFL loading whilst a longer
time on RBZ PRN therapy predicted worse BCVA after
AFL loading. The number of injections did not predict
BCVA at any stage. Predictors of CRT included the CRT
at the beginning of each stage. Higher final CRT was
also predicted by higher CRT and better BCVA post
AFL loading and by worse BCVA and lower CRT after
RBZ loading [see Additional file 1].
RBZ PRN vs. AFL PRN
A comparable trend of disease progression was ob-
served following PRN therapy for both RBZ and AFL.
Table 1 Summary of baseline patient details
Characteristics
No. of participants 182
No. of eyes 207
Mean age (years) ± SD 80 ± 7.7
Female (%) 71
Phakic eyes (%) 78
Mean BCVA (letters) ± SD 29 ±13.2
Mean central retinal thickness (μm) ± SD 342 ± 100
Mean duration of nvAMD at switch (weeks) ± SD 129 ± 86
Mean number of ranibizumab injections at switch ± SD 12 ± 7
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There was a mean loss of 6.7 letters (p < 0001) BCVA
and a mean gain of 24 μm (p < 0.001) after RBZ PRN ther-
apy. Similarly, there was a mean loss of 8.9 letters (p <
0.001) BCVA and a mean gain of 12 μm (p < 0.05) CRT
following PRN treatment with AFL PRN therapy.
In order to investigate whether response to RBZ
PRN treatment correlated with AFL PRN treatment,
we categorised the change in CRT and BCVA during
the RBZ PRN treatment phase into different groups
[see Additional file 2]. Spearman’s rank-order correl-
ation coefficient revealed no significant correlation
between these different groups with respect to change
in CRT or BCVA during AFL PRN, suggesting no sig-
nificant link between RBZ response and AFL response
in our patient cohort.
Data on patients having both eyes treated
A comparison of the data on 25 patients who had both
eyes treated was made with the data from the main
study. The purpose of this was to investigate if the
BCVA and CRT changes across this group were similar
to those in the main study. We also assessed for any
Fig. 2 Change in ETDRS letters with standard error bars
Fig. 3 Change in central retinal thickness with standard error bars
Elwes et al. BMC Ophthalmology  (2018) 18:20 Page 5 of 8
correlation between the data from the two eyes. In
summary, changes in BCVA and CRT for the ‘both
eye’ group were found to be similar to those in the
main study. We found no significant correlation be-
tween the right eye and left eye data for this group
[see Additional file 3].
Switch-back data
Out of 207 study eyes switched to AFL, 7 were
switched back to RBZ after AFL loading due to clin-
ical worsening of intra- or sub-retinal fluid. At switch,
they had received an average of 15 RBZ injections
over a treatment period of 2.2 years. After AFL load-
ing they had a mean loss of 3.8 ETDRS letters and
mean increase of 25 μm CRT. At the final data col-
lection, these patients had been followed-up for an
average of 23 months after switch. By this time, they
had received an average of 4.7 AFL injections and 25
RBZ injections. Compared to post-AFL loading results
they had lost an average of 4.6 ETDRS letters with
no change in mean CRT.
Data on patients not receiving any further IVT injections
Following 3 AFL loading injections, 7 patients continued
under regular follow-up but received no further anti-
VEGF injections. Prior to switch they had received an
average of 6.6 RBZ injections. At the final data collec-
tion, these patients had an average CRT of 213 μm and
average ETDRS score of 56 letters. Compared to results
collected after AFL loading this represented a CRT re-
duction of 34 μm and a loss of 5 ETDRS letters.
Adverse events
Adverse events were monitored during the period of
AFL treatment and are outlined in Table 3. There were
no cases of endophthalmitis.
Discussion
This study compared visual and anatomical outcomes in
nvAMD patients who already appeared to have persist-
ent or recurrent nvAMD on RBZ IVT and subsequently
transitioned to AFL using a PRN dosing schedule after
an initial loading period.
In clinical trials, AFL has been shown to have a similar
efficacy and side effect profile to RBZ but with a longer
dosing interval [17]. It has been suggested that AFL may
be more effective in cases of refractory disease follow-
ing preclinical studies which have shown that VEGF
Trap-Eye binds to VEGF-A with a higher affinity than
other anti-VEGF molecules [18]. Additionally, it also
acts on other molecules that may result in intra- or
sub-retinal fluid such as placental growth factor
(PIGF) which are not inhibited by other anti-VEGF
drugs [18]. We found that a small number of patients
(n = 7) did not require any further treatment after ini-
tial AFL loading. However, an equal number were
also switched back to RBZ due to worsening of intra-
and/or sub-retinal fluid.
The outcomes in this study show that initial visual
gains made by RBZ therapy on treatment-naive eyes are
gradually lost over time using a PRN schedule of treat-
ment. In our study, BCVA and CRT showed significant
correlation in stage 1 but not in stages 2, 3 or 4. This
suggests that at early stages BCVA may mainly be af-
fected by intra- or sub-retinal fluid which is reflected by
CRT. However, at later stages the CRT reflects
remaining neuroretinal thickness rather than intra- or
sub-retinal fluid. Consequently, higher CRT should lead
to better vision. This is supported by findings in stage 4
of our study which found that higher CRT post AFL
loading predicted better final BCVA. We did not meas-
ure neuroretinal thickness separately in this study. Simi-
lar results of a disparity in CRT and BCVA have been
found in long term studies with one anti-VEGF agent
alone using PRN dosing [10, 19–21] and following tran-
sitioning between anti-VEGF agents [22].
A recent systematic review on patients with treatment-
resistant nvAMD on bevacizumab or RBZ subsequently
switched to AFL concluded that switching led to signifi-
cant improvement in CRT but only static BCVA [23]. In
contrast, we found that there was gradual deterioration in
CRTand BCVA with AFL PRN therapy following an initial
improvement with AFL loading. This difference in out-
comes might be explained by the longer mean follow-up
period (24 months) after AFL switch in our study com-
pared to that of the studies (6–12 months) included
by Spooner et al. [23] in their review. A likely inter-
pretation is that a follow-up period of 12 months
Table 2 CRT changes following AFL PRN treatment
CRT reduced N (%) CRT increased N (%)
≥50μm 23 (12%) ≥50μm 38 (21%)
≥100μm 8 (4%) ≥100μm 16 (9%)
Table 3 Adverse events reported during the study
Characteristics Frequency
Significant loss in VA (progressive retinal scarring) 2
Epithelial defect secondary to intravitreal injection 1
Subretinal haemorrhage 1
Subconjunctival haemorrhage 1
Retinal tear requiring retinopexy 1
Atrial fibrillation 1
Stroke 1
VZV infection/Shingles 2
Metastatic cancer diagnosed during treatment 1
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might not be long enough to capture the full long-
term effects of switching to AFL.
There has already been some evidence that outcomes
in routine clinical practice for new medications do not
match the outcomes found in clinical trials where there
are stringent inclusion and exclusion criteria and strict
follow-up schedules [24, 25]. A potential cause of the
deterioration of vision in stage 2 and the subsequent
non-significant improvement of vision and significant
improvement in CRT after AFL loading could be under
treatment. In this study, patients were treated using a
PRN protocol. However, this study compares well with
recently published PRN treatment clinical trials when
comparing numbers of injections per eye per year. The
PrONTO study applied 9.9 injections per eye over two
years using OCT guided increase in fluid as a guide to
retreatment [7]. This approximates to 0.41 RBZ injec-
tions per eye per month. A comparable 0.37 RBZ injec-
tions were performed per eye per month in this study.
Additionally, we did not find that the number of injec-
tions predicted better outcomes in the analysis of this
study which suggests that the patients were not signifi-
cantly undertreated.
There is increasing evidence that tachyphylaxis with
anti-VEGF agents may play a part in reduction of clinical
efficacy with time [26, 27]. In our study, some of the ef-
fect may also be a result of tachyphylaxis to RBZ and
the subsequent benefit of switching anti-VEGF agents. It
is unclear whether a change to another anti-VEGF agent
such as bevacizumab would also have resulted in similar
short term improvements as has been reported else-
where [28]. Tachyphylaxis to AFL treatment may also
explain the progressive worsening of visual acuity and
CRT following longer term treatment with AFL in stage
4 [29]. In our study only seven patients were reverted
back to RBZ due to clinical failure of AFL. It would
be interesting to see the effects on CRT and BCVA of
switching back more patients to RBZ in a future
study in order to estimate the effect of tachyphylaxis
on clinical response.
A limitation of our study may be the retrospective re-
view of notes to obtain data. The retrospective data re-
lies on the quality of record keeping to ensure accuracy
of the data and may particularly affect history, examin-
ation findings and BCVA. Nonetheless, measurements
were taken at each visit and as a result an objective
measure of CRT was obtained for each time point.
Long-term data comparing RBZ and AFL injection fre-
quency has suggested a reduced required injection fre-
quency with AFL using a treat and extend protocol [30].
However, we found that the number of injections re-
quired for treatment increased with an AFL PRN treat-
ment regime. 0.47 AFL injections per eye per month
were performed compared to 0.37 RBZ injections per
eye per month. Our study is unable to provide direct
comparison of injection rates as no control group was
used and AFL treatment was performed on those previ-
ously treated with RBZ and not on treatment naïve pa-
tients. Despite the increased injection rate with AFL we
continued to notice a decline in visual acuity again con-
firming that a degenerative process may have already
started prior to switch which could not be halted by
AFL therapy. A future study plans to examine a cost-
benefit analysis of transitioning patients to AFL on a
PRN basis as we found that there was an increase in the
number of injections required with AFL which may neg-
ate the possible cost savings reported [22].
Conclusion
In summary, this study finds that in patients with
nvAMD who are treated with PRN RBZ therapy, macu-
lar anatomy is significantly improved following AFL
loading. However, this real world clinical data shows
that, in the longer term, AFL does not halt the slow de-
terioration in BCVA and CRT which occurs in patients
switched from RBZ despite a higher injection rate using
PRN AFL dosing.
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